Spectrum Pharmaceutical is paying US$30 M upfront for TopoTarget’s Phase III lymphoma drug, belinostat, a histone deacetylase (HDAC) inhibitor in development for the treatment of peripheral T cell lymphoma (PTCL). The drug has been granted orphan drug and fast track designation by the FDA.